| Elizabeth Mary Westbrook, CRNP | |
|
402 Coventry Dr, Phillipsburg, NJ 08865-1969 | |
| (908) 454-3000 | |
| Not Available |
| Full Name | Elizabeth Mary Westbrook |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Women's Health |
| Location | 402 Coventry Dr, Phillipsburg, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285820324 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SW0102X | Clinical Nurse Specialist - Women's Health | 26NN06489700 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth Mary Westbrook, CRNP 1800 N Delaware Dr, Easton, PA 18040-7319 Ph: (610) 923-8275 | Elizabeth Mary Westbrook, CRNP 402 Coventry Dr, Phillipsburg, NJ 08865-1969 Ph: (908) 454-3000 |
News Archive
Doctors in Canada have discovered that treating high-risk prostate cancer patients with radiation therapy and adding hormone therapy for more than one year allows patients to live longer, have better control of their prostate specific antigen levels and lowers the rate of death specifically from prostate cancer
French researchers have found that drinking only a small glass of sugary drink per day could lead to a whopping 18 percent increase in the risk of cancer and a 22 percent increase in breast cancers. The team published their study titled, "Sugary drink consumption and risk of cancer: results from NutriNet-Santé prospective cohort," was published in the latest issue of the British Medical Journal.
Northeast Pennsylvanians often think that excellent cancer care is found strictly in larger cities. However, that perception was recently disproved by Scranton's own Northeast Radiation Oncology Center (NROC).
Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute's capabilities for studying and treating lung cancer.
A new combination vaccine may reduce the number of injections required to keep infants and toddlers up to date with the United States infant immunization schedule recommended by the Centers for Disease Control and Prevention. In a phase III trial reported in the August 2015 issue of Pediatrics, the vaccine was determined to be effective, safe and well-tolerated. Gary S. Marshall, M.D., professor of pediatrics at the University of Louisville, was the principal investigator of the multi-center trial and first author of the report.
› Verified 1 days ago